These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 33850002)

  • 1. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of
    Tang TT; Konradi AW; Feng Y; Peng X; Ma M; Li J; Yu FX; Guan KL; Post L
    Mol Cancer Ther; 2021 Jun; 20(6):986-998. PubMed ID: 33850002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.
    Kulkarni A; Mohan V; Tang TT; Post L; Chan YC; Manning M; Thio N; Parker BL; Dawson MA; Rosenbluh J; Vissers JH; Harvey KF
    EMBO Rep; 2024 Sep; 25(9):3944-3969. PubMed ID: 39103676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
    Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
    Elife; 2022 Nov; 11():. PubMed ID: 36398861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity.
    Kim NG; Gumbiner BM
    Proc Natl Acad Sci U S A; 2019 May; 116(20):9877-9882. PubMed ID: 31043565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma.
    Papavassiliou KA; Sofianidi AA; Papavassiliou AG
    J Cell Mol Med; 2024 Apr; 28(8):e18330. PubMed ID: 38606782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    Laraba L; Hillson L; de Guibert JG; Hewitt A; Jaques MR; Tang TT; Post L; Ercolano E; Rai G; Yang SM; Jagger DJ; Woznica W; Edwards P; Shivane AG; Hanemann CO; Parkinson DB
    Brain; 2023 Apr; 146(4):1697-1713. PubMed ID: 36148553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumor suppressor NF2 modulates TEAD4 stability and activity in Hippo signaling via direct interaction.
    Wu M; Hu L; He L; Yuan L; Yang L; Zhao B; Zhang L; He X
    J Biol Chem; 2024 May; 300(5):107212. PubMed ID: 38522513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
    Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
    ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 16. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
    Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
    Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor.
    Moure CJ; Vara B; Cheng MM; Sondey C; Muise E; Park E; Vela Ramirez JE; Su D; D'Souza S; Yan Q; Yeung CS; Zhang M; Mansueto MS; Linn D; Buchanan M; Foti R; DiMauro E; Long B; Simov V; Barry ER
    Mol Cancer Ther; 2024 Aug; 23(8):1095-1108. PubMed ID: 38691847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.
    Holden JK; Crawford JJ; Noland CL; Schmidt S; Zbieg JR; Lacap JA; Zang R; Miller GM; Zhang Y; Beroza P; Reja R; Lee W; Tom JYK; Fong R; Steffek M; Clausen S; Hagenbeek TJ; Hu T; Zhou Z; Shen HC; Cunningham CN
    Cell Rep; 2020 Jun; 31(12):107809. PubMed ID: 32579935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells.
    Sun Y; Hu L; Tao Z; Jarugumilli GK; Erb H; Singh A; Li Q; Cotton JL; Greninger P; Egan RK; Tony Ip Y; Benes CH; Che J; Mao J; Wu X
    Nat Commun; 2022 Nov; 13(1):6744. PubMed ID: 36347861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
    Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
    Elife; 2022 Oct; 11():. PubMed ID: 36300789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.